Lagevrio questions, mRNA jab misunderstandings and nasal vaccines coming
Manage episode 344368145 series 3382357
Episode 207
Despite a panoramic study suggesting a lower effect, Lagevrio has a useful impact on hospitalisations, deaths and shorter recovery time
COVID trials becoming more difficult to run because so many people have either been vaccinated and / or exposed
How the Pfizer vaccination’s lack of impact on transmission is not a cause for concern and was clearly communicated since its release. The main impact is the reduction of severity, hospitalisations and death, and the data for this hasn’t changed
How a nasal vaccination might be coming
Host: David Lim | Total Time: 21 mins
Guest: A/Prof Paul Griffin, Infectious Diseases Physician and Clinical Microbiologist
Register for our fortnightly FREE WEBCASTS
Every second Tuesday | 7:00pm-9:00pm AEDT
Click here to register for the next one
See omnystudio.com/listener for privacy information.
100 episodios